These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
4. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
5. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Beghetti M Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary arterial hypertension: a current review of pharmacological management. Sahni S; Ojrzanowski M; Majewski S; Talwar A Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827 [TBL] [Abstract][Full Text] [Related]
12. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [TBL] [Abstract][Full Text] [Related]
13. [The current pharmacotherapy of pulmonary arterial hypertension]. Betkier-Lipińska K; Ryczek R; Cwetsch A Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586 [TBL] [Abstract][Full Text] [Related]
14. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL; Michelakis ED Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [TBL] [Abstract][Full Text] [Related]
15. Drug treatment of pulmonary hypertension in children. Vorhies EE; Ivy DD Paediatr Drugs; 2014 Feb; 16(1):43-65. PubMed ID: 24114695 [TBL] [Abstract][Full Text] [Related]
16. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Suleman N; Frost AE Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760 [TBL] [Abstract][Full Text] [Related]
18. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443 [TBL] [Abstract][Full Text] [Related]
19. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. Levy M; Bonnet D; Mauge L; Celermajer DS; Gaussem P; Smadja DM PLoS One; 2013; 8(6):e65114. PubMed ID: 23762293 [TBL] [Abstract][Full Text] [Related]
20. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Sakao S; Tanabe N; Kasahara Y; Tatsumi K Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]